Past studies

This is an observational study to look at the effectiveness of current Standard of Care (SOC) treatments and the course of depressive symptoms in patients with Major Depressive Disorder (MDD) with anhedonia.

Randomised placebo controlled trial of Pramipexole addition to mood stabilisers for treatment resistant bipolar depression. PAX-BD was a major trial examining a novel treatment for bipolar disorder, funded by the NIHR HTA Board.

The SCiD study is looking at how sleep affects the brain and cognition in patients ages 18-65 with a diagnosis of depression.

Randomised placebo-controlled trial evaluating the efficacy and mechanism of pramipexole as add-on treatment for people with treatment resistant depression.

The Psilocybin Study was a multi-centred worldwide clinical trial examining the safety and efficacy of psilocybin (the ‘magic’ in ‘magic mushrooms’) in participants with treatment-resistant depression.

R-LiNK is an EU-funded, multicentre longitudinal observational study that aims to determine which individuals with bipolar I disorder are most eligible for long-term lithium treatment in terms of response, safety and tolerability.

Lithium can effectively treat and prevent mania and depression, as well as reduce risk of suicide. However, it does not work for everyone. The BLISS is examining why lithium is an effective treatment for some patients with bipolar disorder but not others, using magnetic resonance techniques.

This study assessed sleep in patients with bipolar compared to healthy patients. It was found that patients with bipolar disorder had high rates of sleep problems, including insomnia, over-sleeping, obstructive sleep apnoea, and inconsistent patterns of going to sleep and waking up.

Electroconvulsive therapy (ECT) is an effective treatment for depression but has many side effects, particularly memory problems. This study explored whether ketamine may protect against memory problems from ECT. The results showed that ketamine made no difference to the beneficial effect of ECT.

Clinicians have worked collaboratively with young people and their families to develop an App for mood monitoring for young people aged 15-25 years with Early Onset Bipolar Disorder.

The CAPMEM study is exploring whether the autonomic nervous system works differently in people with mental health, neurodevelopmental, and neurodegenerative disorders and whether this explains the memory and concentration problems in these populations.

The ALFI study is examining the psychometric properties of a newly developed questionnaire (“ALFI”) in a sample of typically developing young people aged 16-25 years, to more accurately measure adaptive functioning in this population.

The RESTORE-LIFE study looking at the effectiveness and efficiency of Vagus Nerve Stimulation (VNS) in difficult to treat patients with depression.

The EOD-UK & ROI study is investigating the incidence of first time diagnosis, management, clinical presentations, and outcome for children diagnosed with Early Onset Depression.

EPICC-ID is a trial evaluating the clinical and cost effectiveness of a parenting group, Level 4 Stepping Stones Triple P (SSTP), designed to reduce challenging behaviour in preschool children with a moderate to severe intellectual disability.